DaVita Inc
1DVA
Company Profile
Business description
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Contact
2000 16th Street
DenverCO80202
USAT: +1 720 631-2100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Care Facilities
Fiscal Year End
31 December 2026
Employees
78,000
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar analysts’ take on the takeover for this undervalued industrial player.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.10 | 3.60 | -0.04% |
| CAC 40 | 8,146.19 | 81.17 | 1.01% |
| DAX 40 | 25,603.14 | 299.08 | 1.18% |
| Dow JONES (US) | 51,682.64 | 95.40 | -0.18% |
| FTSE 100 | 10,771.23 | 112.10 | 1.05% |
| HKSE | 25,042.71 | 291.93 | 1.18% |
| NASDAQ | 26,522.54 | 104.25 | 0.39% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.20 | 82.06 | 0.60% |
| S&P 500 | 7,650.50 | 12.74 | 0.17% |
| S&P/ASX 200 | 8,731.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,949.91 | 38.04 | 0.97% |